Strategy
The segment selected as Duphaston’s growth opportunity due to it’s sizable market size
Menstrual Disorders (Specifically Irregular Cycle)
The G3D segment that contributes the largest share of both market volume and value, making it strategically important despite limited overall growth.
Pregnancy
The position Abbott regained in the Egyptian Women’s Health market on a MAT August 2026 basis.
5th place, returning Abbott to the top five Women’s Health companies
Which tactic uses KOL-led events to strengthen peer-to-peer education across Pregnancy and Menstrual Disorders?
The Women’s Journey Speaker Program, delivered through regional events to strengthen advocacy, share clinical experience, and reinforce approved scientific messages.
Which three modules are included in the Level Up refresher program
Duphaston, Femoston, and Pharmacist Messages
The strategic role assigned to the pregnancy segment because of its large contribution, high competitive intensity, and Duphaston’s leadership position
Defend and protect leadership while capturing additional share from MVPs.
The molecule dominating the Menstrual Disorders segment and representing the primary source of competitive share for Duphaston. And it’s share of MD market
Norethisterone, with 79% of the segment in the presented FY2025 analysis
The two August YTD 2026 market-share results demonstrating Duphaston’s leadership in G3D.
34.9% standard-volume market share and 34% value market share
Which small-group scientific tactic targets habitual norethisterone prescribers and encourages evidence-based discussion around menstrual-cycle regulation? And who do we target?
The Menstrual Regulator Roundtable Discussions, targeting relevant MD experts through focused peer-to-peer scientific exchange. And we target Top Norethisterone prescribers
What are the three steps in the Level Up learning approach
Watch, Practice, and Check
The strategic choice required to grow Duphaston in infertility, where prescribing is driven by established clinical practice
Strengthen scientific positioning, increase targeted IVF engagement, and support inclusion in IVF protocols
The market development that shifted Duphaston’s competitive landscape from molecule-level competition to both molecule and brand-level competition
The entry of dydrogesterone generics beginning in Q4 2024
The two first-mover achievements that established Femoston as a market-shaping brand in Egypt.
Creating the menopause market and challenging the status quo by alleviating HCP fears around MHT
Who do we target most through long-term educational program? And mention an example with details for this type of engagement.
HCPs at higher risk of switching to generics. The Hormonal Mastery Diploma provides structured, long-term education across Pregnancy, IVF, and Menstrual Disorders to deepen scientific knowledge
What are the three winning fundamentals required to convert the Women’s Health strategy into consistent field performance?
Enhancing HCP engagement and loyalty, team upskilling, and execution excellence with performance tracking
The three patient-flow leverage points that Femoston’s strategy must prioritize to create sustainable growth
Correct diagnosis, appropriate MHT prescription and Femoston adoption, and treatment continuation for 3 to 4 months
The segment where progesterone holds the leading position, but dydrogesterone maintains a meaningful share and potential for expansion through targeted scientific engagement. And mention the current molecule shares
Infertility, where the presented analysis shows progesterone at 61% and dydrogesterone at 39%
The highest monthly Femoston volume achieved in the presented 2025–2026 performance trend, together with the month in which it was achieved
14,017 units in September 2026
Which product is targeted through the PHI channel, which receives only 5% of our time, and what tactics do we use?
Hyal. Focus on contracted HCPs and hospitals, while driving prescriptions from non-contracted HCPs to extend influence
How should field execution differ according to each brick’s main opportunity
Pregnancy bricks: Protect leadership and capture more share from MVPs.
Priority MD bricks: Focus on high-potential norethisterone prescribers.
Generic-risk bricks: Prioritize HCPs most likely to switch to generics and strengthen scientific engagement.
The portfolio strategy that balances short-term business protection with future Women’s Health growth.
Defend Duphaston leadership in pregnancy, grow Duphaston in Menstrual Disorders and IVF, mitigate generic erosion, and accelerate Femoston through diagnosis, adoption, adherence, and availability
The projected Femoston patient opportunity in 2027 and the two market considerations needed to capture it.
Approximately 45,000 patients. Capturing this opportunity requires improving numeric distribution and monitoring Livial and Veozah, while continuing to expand the market. We do not compete directly against them
Which 2026 initiative improved field execution across Pregnancy and Menstrual Disorders, and how did it strengthen territory focus?
Your organization's data cannot be pasted here. Only 256 characters are allowed.
A territory has active Femoston prescribers, but prescriptions are being lost because availability is inconsistent. Explain the tactical response.
Target priority pharmacies near active prescribers.
Expand numeric distribution.
Monitor stock availability.
Track prescription fulfilment and leakage.
What does winning execution look like at brick level?
Set clear priorities for each brick.
Focus engagement on the right HCPs.
Deliver the right product message with confidence.
Secure a specific commitment and next action.
Track prescriptions, share, competition, and availability.